

Curriculum Vitae



Curriculum Vitae

Personal information

Personal information

First name(s) / Surname(s)

First name(s) / Surname(s)
Chiara Maria Grana

Chiara Maria Grana

Work Address

Work Address
Via Ripamonti, 435 – 20141 Milano

Via Ripamonti, 435 – 20141 Milano

Home Address

Viale Giovanni Suzzani, 269 - 20162 Milano

Telephone(s)

+39 02.57489044

Telephone(s)

+39 02.57489047-44

+39 3371217744

Fax(es)

+39 02.94379223

E-mail

chiara.grana@ieo.it

E-mail

chiara.grana@ieo.it – divisione.medicinanucleare@ieo.it

Nationality

Italian

Nationality

Italian

Date of birth

September 13, 1964

Date of birth

September 13, 1964

Place of birth

Milan - Italy

Place of birth

Milan - Italy

Language Spoken

Language Spoken
Italian (Mother language) English (Excellent),

Italian (Mother language) English (Excellent),

Work experience

Work experience

Dates

Since April 2014

Since April 2014

Director of the Division of Nuclear Medicine at IEO, Milano

Since Novembre 2013

Since November 2013

Acting Director of the Division of Nuclear Medicine at IEO, Milano – Italy

From July 2001 to October 2013

From July 2001 to October 2013

Deputy Director of the Division of Nuclear Medicine at IEO, Milano – Italy

From 1995 to 2001

From 1995 to 2001

Assistant of the Division of Nuclear Medicine at IEO, Milano – Italy

Education and training

Education and training

2003

1990 M.D., Medicine and Surgery, Università degli Studi di Milano (Milano, Italy) cum laude

1994

1994 Post-doctorate in Nuclear Medicine, Università degli Studi di Milano (Milano, Italy)

1990 M.D., Medicine and Surgery, Università degli Studi di Milano (Milano, Italy) cum laude

2003 Post-doctorate in Oncology, Università degli Studi di Milano (Milano, Italy), final grades 110/110

Research Activities

Clinical Activities carried out at IEO

She works in the field of radiometabolic therapy in thyroid diseases, emitters in brain tumors and in non-Hodgkin lymphomas. Moreover radionuclide receptor therapy and diagnosis with radiopeptides labelled malignancies.

She deals with traditional nuclear medicine techniques, with the treatment with the out-patient activity.

Research and Clinical Activities

Clinical Activities carried out at IEO

She works in the field of radiometabolic therapy in thyroid diseases, in radioimmunotherapy with β -emitters in brain tumors and in non-Hodgkin lymphomas. Moreover she works in the field of radionuclide receptor therapy and diagnosis with radiopeptides labelled with β -emitters in endocrine malignancies. She is the leading person in nuclear medicine in the field of neuroendocrine tumors at IEO, coordinating the nuclear medicine diagnosis and therapy for neuroendocrine malignancies. She is an active member of the multidisciplinary tumor board (ENETS Center of Excellence in neuroendocrine tumours). She deals with traditional nuclear medicine techniques, with the treatment of bone metastases (Radium-223) and with the out-patient activity.

Therapeutic applications of Nuclear Medicine in Oncology:

- Since 1997: Peptide Receptor Radionuclide Therapy in neuroendocrine Tumors
- Translational research applied to radiopeptide therapy.
- Development of a probe for radioguided surgery in meningioma and neuroendocrine tumors patients.
- Radioimmunotherapy with beta-emitters by means of avidin-biotin system: loco-regional and systemic administration in brain tumors and ovarian carcinoma.
- Radioimmunotherapy with antibodies radiolabelled with beta-emitters in NHL
- Internal dosimetry in radionuclide diagnosis and therapy.
- Radionuclide therapy of differentiated thyroid cancer and hyperthyroidism with ¹³¹I.
- Radionuclide therapy in bone metastases (Radium-223)

Diagnostic applications of Nuclear Medicine in Oncology:

- Receptor scintigraphy with radiolabelled peptides.
- Radioimmunoscintigraphy with avidin-biotin system.
- PET/TC in Oncology.
- Laboratory Nuclear Medicine in tumor diagnosis.
- Routine diagnostic examinations

Research Activities carried out at IEO

She works in the research field of brain and haematological malignancies, in particular in non-Hodgkin's Lymphoma with Zevalin, by co-ordinating radioimmunotherapy protocols. She participated as a clinical investigator in different radioimmunotherapy protocols.

She contributed actively to the development both of different applications of lymphoscintigraphy and of antibodies with the avidin-biotin system in patients with solid tumors (ovarian, glioma, breast, colon and melanoma).

She participated in many clinical trials with Peptide Receptor Radionuclide Therapy in NET patients and in studying bombesin analogues, radiolabelled with beta-emitters.

She has experience in GCP trials, and coordinate, studies in diagnostic of prostate cancer.

Passed Clinical and Research Activities

1994 Attending physician at the Spedali Civili – Brescia – Radiometabolic Division

1990-1994 Fellow, Istituto Scientifico San Raffaele, Milano - Italy.

1989 Visiting student at the Department of Internal medicine of the University of Nijmegen (The Netherlands)

1988 – 1990 Student, Istituto Scientifico San Raffaele – Milano, Nuclear Medicine Division

1988 Visiting student at the State Hospital in Bratislava, Slovak Republic

1986 – 1988 Student, Ospedale Niguarda Ca' Granda – Milano, General Medicine Division

Other activities

Outpatient visits (particularly in patients affected by neuroendocrine tumors, thyroid cancer, prostate cancer)

Additional information

From 2006 to 2012 Tutor school of specialization in nuclear medicine, University of Milan

Since 2007 appointed teacher at the School of Specialization in Oncology, University of Parma

Since 2010 appointed teacher at the School of Radiological Techniques, University of Milano

Since 2013 appointed teacher at the School of Specialization in Nuclear Medicine and Molecular Imaging Oncology, University of Milan

Since 2014 Lecturer at a Master in Oncological Nursing in Nuclear Medicine and Molecular Imaging Oncology, University of Milan

Since 1994 Member of the Italian Association of Nuclear Medicine (AIMN)

She is an active member of the Neuroendocrine and the Neck Surgery task forces (multidisciplinary tumor board) in IEO

She is the person in charge for the Quality process and also collaborated in the ISO 9001 Certification process for the Division of Nuclear Medicine at IEO, Milano – Italy.

Congresses

She spoke in numerous national and international congresses and participated at several international meetings about NET

Publications

She published more than 80 articles on international peer-reviewed journals, 8 invited book chapters and 9 publications on national journals, besides several abstracts on international and national congresses.

Milan, October 12nd, 2017

I authorize the treatment of my personal data according to the Italian law D.L. 196 (30/06/2003)

PUBLICATIONS

- A1** - Tommasino C, **Grana C**, Lucignani G, Beretta L, Torri G, Fazio F. Cerebral metabolism with PET methods in patients in coma and in postcomatose syndrome. A prognostic index? *Minerva Anestesiol*, 59: 837-841, 1993
- A2** - Messa C, **Grana C**, Lucignani G, Fazio F. Functional Imaging Using PET and SPECT in pediatric neurology. *J Nucl Biol Med* 38: 85-88, 1994
- A3** - Balestri P, Lucignani G, Fois A, Magliani L, Calistri L, **Grana C**, Di Bartolo RM, Perani D, Fazio F. Cerebral glucose metabolism in neurofibromatosis type 1 assessed with [18F]-2-fluoro-2-deoxy-D-glucose and PET. *J Neurol Neurosurg Psych* 57:1479-83; 1994
- A4** - Lucignani G, Del Sole A, **Grana C**, Rizzo G, Messa C, Moresco RM, Landoni C, Fazio F. Synergistic neuroimaging in epilepsy. In: *Epilepsie '93*, Eds. Herausgegeben von H Stefan, R. Canger, G. Spiege, 561-565, 1994
- A5** - Paganelli G, Samuel A, Magnani P, Songini C, **Grana C**, Nacci G, Siccardi AG, Fazio F. Diagnosis of solid tumors using antibodies. *Minerva Biot*, 6 (4), 1-9, 1995.
- A6** - Tommasino C, **Grana C**, Lucignani G, Torri G, Fazio F. Regional cerebral metabolism of glucose in comatose and vegetative state patients. *J Neurosurg Anesth*, 7: 109-116, 1995
- A7** - Franceschi M, Lucignani G, Del Sole A, **Grana C**, Bressi S, Minicucci F, Messa C, Canevini MP, Fazio F. Increased interictal cerebral glucose metabolism in a cortical-subcortical network in drug-naïve patients with cryptogenic temporal lobe epilepsy. *J of Neurol Neurosurg Psych*, 59: 427-431, 1995
- A8** - Lucignani G, Tassi L, Fazio F, Galli L, **Grana C**, Del Sole A, Hoffman D, Francione S, Minicucci F, Kahane P, Messa C, Munari C. Double-blind stereo-EEG and FDG PET study in severe partial epilepsies: are the electric and metabolic findings related? *Eur J Nucl Med*, 23: 1498-1507, 1996
- A9** - **Grana C**, Chinol M, Magnani P, Corti A, Sidoli A, Siccardi AG, Paganelli G. In vivo tumor targeting based on the avidin-biotin system. *Tumor Targeting*, 2 (4): 230-239, 1996
- A10** - Testori A, **Grana C**, Bartolomei M, Stoldt HS, Ukpabi E, Gennari R, Paganelli G, Fiorenza M, Geraghty JM. Lymphoscintigraphy with antimelanoma monoclonal antibody to detect micrometastases of the sentinel node in melanoma patients. *Gastroent Int*, 10 (3): 845-846, 1997
- A11** - De Cicco C, Cremonesi M, Luini A, Bartolomei M, **Grana C**, Prisco G, Galimberti V, Calza P, Viale G, Veronesi U, Paganelli G. Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. *J Nucl Med*, 39: 2080-2084; 1998.(1st Place Award for Outstanding Clinical Investigation-Journal of Nuclear Medicine 1998).
- A12** - Paganelli G, Orecchia R, Jereczek-Fossa B, **Grana C**, Cremonesi M, De Braud F, Tradati N, Chinol: Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. *Eur J Nucl Med*, 25: 9, 1998
- A13** - Cremonesi M, Ferrari M, Chinol M, Stabin MG, **Grana C**, Prisco G, Robertson C, Tosi G, Paganelli G. Three-step radioimmunotherapy with 90Y-biotin dosimetry and pharmacokinetics in cancer patients. *Eur J Nucl Med* 26: 110-120, 1999
- A14** - Paganelli G, **Grana C**, Chinol M, Cremonesi M, De Cicco C, De Braud F, Robertson C, Zurrida S, Casadio C, Zoboli S, Siccardi AG, Veronesi U. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. *Eur J Nucl Med* 26: 348-357, 1999
- A15** - Testori A, Bartolomei M, **Grana C**, Mezzetti M; Chinol M, Mazzarol G, Lazzari I, Paganelli G, Andreoni B, Veronesi U. Sentinel node localization in primary melanoma: learning curve and results. *Melanoma Research*, 9: 587-593, 1999
- A16** - De Cicco C, Sideri M, Bartolomei M, **Grana C**, Cremonesi M, Maggioni A, Bocciolone L, Mangioni C, Colombo N, Paganelli G. Sentinel node biopsy in early vulvar cancer. *Br J Can* 82: 295-299, 2000
- A17** - Chiesa F, Mauri S, **Grana C**, Tradati N, Calabrese L, Mohssen A, Mazzarol G, Paganelli G. Is there a role for sentinel node biopsy in early N0 tongue tumours?. *Surgery*, 128: 16-21, 2000
- A18** - Magnani P, Fazio F, **Grana C**, Songini C, Frigerio L, Pecorelli S, Mangili G, Colombo N, Mariani A, De Cicco C and Paganelli G. Diagnosis of persistent ovarian carcinoma with 3-step immunoscintigraphy. *Br J Can*, 82(3): 616-620, 2000
- A19** - Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, **Grana C**, Bartolomei M, Orsi F, De Cicco C, Maecke HR, Chinol M and de Braud F. Receptor-mediated radiotherapy with 90Y-DOTA-d -Phe1-Tyr3-octreotide. *Eur J Nucl Med*, 28: 426-434, 2001

- A20** - Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G, Sturiale C, **Grana C**, Prisco C, Gatti M, Caliceti P, Chinol M. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results. *Can Biother & Radiopharm*, 16: 227-235, 2001
- A21** - **Grana C**, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P and Paganelli G. Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: a pilot study. *Brit J Cancer*, 86: 207-212, 2002.
- A22** - Bodei L, Cremonesi M, Zoboli S, **Grana C**, Bartolomei M, Rocca P, Caracciolo M, Maecke HR, Chinol M and Paganelli G. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. *Eur J Nucl Med Mol Imaging*, 30: 207-216, 2003
- A23** - Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, Gatti M, Chinol M, Bartolomei M, Fiorenza M, **Grana C**.: 90Y-DOTA-D-Phe1-Tyr3-octreotide in therapy of neuroendocrine malignancies. *Biopolymers*. 2002; 66(6):393-8
- A24** - Bodei L, Handkiewicz Junak D, **Grana C**, Rocca P, Bartolomei M, Gibelli B, Cremonesi M, Chinol M, Paganelli G. Receptor radiotherapy with 90Y-DOTATOC in patients with advanced medullary thyroid carcinomas. *Cancer Biotherapy and radiopharmaceuticals* 2003;18(2):281
- A25** - **Grana C**, Bartolomei M, Handkiewicz D, Rocca P, Bodei L, Colombo N, Chinol M, Mangioni C, Malavasi F, Paganelli G. Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with 90Y-biotin? *Gynecol Oncol*. 2004 Jun;93(3):691-8.
- A26** - Bodei L, Cremonesi M, **Grana C**, Rocca P, Bartolomei M, Chinol M, Paganelli G. Receptor radionuclide therapy with (90)Y-[DOTA](0)-Tyr(3)-octreotide ((90)Y-DOTATOC) in neuroendocrine tumours. *Eur J Nucl Med Mol Imaging*. 2004 Jul;31(7):1038-46
- A27** - Bodei L, Handkiewicz-Junak D, **Grana C**, Mazzetta C, Rocca P, Bartolomei M, Lopera Sierra M, Cremonesi M, Chinol M, Macke HR, Paganelli G. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. *Cancer Biother Radiopharm*. 2004 Feb;19(1):65-71.
- A28** - Chiesa F, Tradati N, Calabrese L, Gibelli B, Giugliano G, Paganelli G, De Cicco C, **Grana C**, Tosi G, DeFiori E, Cammarano G, Cusati A, Zurrada S. Thyroid disease in northern Italian children born around the time of the Chernobyl nuclear accident. *Ann Oncol*. 2004 Dec;15(12):1842-6.
- A29** - Bartolomei M, Mazzetta C, Handkiewicz-Junak D, Bodei L, Rocca P, **Grana C**, Maira G, Sturiale C, Villa G, Paganelli G. Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. *Q J Nucl Med Mol Imaging*. 2004 Sep;48(3):220-8.
- A30** - Agazzi A, Rocca P, Laszlo D, Bodei L, **Grana C**, Martinelli G, Paganelli G. Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders? *Eur J Haematol*. 2005 May;74(5):450-1.
- A31** - Paganelli G, Bartolomei M, **Grana C**, Ferrari M, Rocca P, Chinol M. Radioimmunotherapy of brain tumor. *Neurol Res* 28 (5): 518-22, 2006.
- A32** - Fazio N, **Grana C**, Pelosi G, Torrisi R, Di Meglio G, Tradati N, Lorizzo K, de Braud F. Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma. Letter to the editor. *Acta Oncologica* 45:627-629, 2006.
- A33** - Palumbo G, **Grana C M**, Cocca F, De Santis R, Del Principe D, Baio SM, Mei R, Paganelli G. Pretargeted antibody-guided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma. *Eur J Haematol*. 2007 Jul 26
- A34** - Ferrucci PF, Vanazzi A, **Grana C M**, Cremonesi M, Bartolomei M, Chinol M, Ferrari M, Radice D, Papi S, Martinelli G, Paganelli G. High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. *Br J Haematol*. 2007 Nov;139(4):590-9.
- A35** - Cremonesi M, Ferrari M, **Grana C M**, Vanazzi A, Stabin M, Bartolomei M, Papi S, Prisco G, Ferrucci PF, Martinelli G, Paganelli G. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. *J Nucl Med*. 2007 Nov;48(11):1871-9. Erratum in: *J Nucl Med*. 2007 Dec;48(12):2027.
- A36** - Bodei L, Cremonesi M, Ferrari M, Pacifici M, **Grana C M**, Bartolomei M, Baio SM, Sansovini M, Paganelli G. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with (90)Y-DOTATOC and (177)Lu-DOTATATE: the role of associated risk factors. *Eur J Nucl Med Mol Imaging*. 2008 Oct;35(10):1847-56.
- A37** - P.F. Ferrucci, A. Vanazzi, C. Crosta, G. Pruneti, **C. Grana**, M. Bartolomei, G. Paganelli, G. Martinelli Efficacy of 90Y Ibritumomab-Tiuxetan Treatment in a case of Resistant Gastric Malt Non Hodgkin's Lymphoma. *Ecancermedicallscience*, 2008.
- A38** - Sauer S, Erba PA, Menrad A, Giovannoni L, **Grana C**, Hirsch B, Zardi L, Paganelli G, Mariani G, Neri D, Dürkop H, Menssen HD. Expression of the oncofetal ed-b containing fibronectin isoform in hematologic tumors. *Blood*. 2009 Jan 8.
- A39** - L. Bodei, D. Ferone, **C M Grana**, M. Cremonesi, A. Signore, R. Diercks and G. Paganelli. Peptide Receptor Therapies in Neuroendocrine Tumours. *Journal of Endocrinological Investigation*, 2009 Apr;32(4):360-9.

- A40** - D. Aricò, **C M Grana**, A Vanazzi, A. Mallia, M Sansovini, G Martinelli, G Paganelli, M Cremonesi. The role of dosimetry in the high activity 90Y-ibritumomab Tiuxetan regimens: Two cases of abnormal Biodistribution. *Cancer Biother Radiopharm.* 2009 Apr;24(2):271-5.
- A41** - Fazio N, Luca F, Monfardini L, Pelosi G, Bodei L, Lorizzo K, Di Meglio G, Gibelli G, Ravizza D, Bonomo G, **Grana C M**, Baio S, Squadroni M, Paganelli G, and de Braud F. Right pelvic mass in a patient with a radically resected carcinoid of the appendix. *GUT*, 2009, Sep;58(9):1200, 1259.
- A42** - Bartolomei M, Bodei L, De Cicco C, **Grana CM**, Cremonesi M, Botteri E, Baio SM, Aricò D, Sansovini M, Paganelli G. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. *Eur J Nucl Med Mol Imaging.* 2009 Mar 25.
- A43** - S. Papi, L. Martano, L. Garaboldi, A. Rossi, M. Cremonesi, **C. M. Grana**, D. Paolucci, M. Sansovini, G. Paganelli, M. Chinol. Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin). *Nucl Med Biol.* 2010 Jan;37(1):85-93.
- A44** - Andrea Piccin, **Chiara Maria Grana**, Giovanni Negri, Irene Pusceddu, Giovanni Paganelli, Sergio Cortelazzo. Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy. Letter to the Editor. *Ann Hematol.* 2011 Apr 21.
- A45** - Bodei L, Cremonesi M, **Grana CM**, Fazio N, Iodice S, Baio SM, Bartolomei M, Lombardo D, Ferrari ME, Sansovini M, Chinol M, Paganelli G. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE: the IEO phase I-II study. *Eur J Nucl Med Mol Imaging.* 2011 Sep 3.
- A46** - P A Erba, M Sollini, E Orciuolo, C Traino, M Petrini, G Paganelli, E Bombardieri, **C M Grana**, L Giovannoni, D Neri, H Menssen, G Mariani. Radioimmunotherapy with Radretumab (131I-L19SIP) in Patients with Relapsed Hodgkin Lymphoma or Other Lymphoproliferative Malignancies. *J Nucl Med.* 2012 May 10.
- A47** - Pistilli B, **Grana C**, Fazio N, Cavaliere A, Ferrari M, Bodei L, Baio S, Scambia G, Paganelli G, Peccatori F. Pregnant with metastatic neuroendocrine tumour of the ovary: what now? *Ecancermedicalscience.* 2012;6:240.
- A48** - Bodei L, Cremonesi M, **Grana CM**, Chinol M, Baio SM, Severi S, Paganelli G. Yttrium-labelled peptides for therapy of NET. *Eur J Nucl Med Mol Imaging.* 2012 Feb;39 Suppl 1:S93-102.
- A49** - **Chiara M. Grana**, Marco Chinol, Concetta De Cicco, Mirco Bartolomei, Marta Cremonesi, Lisa Bodei, Paola A. Rocca, Monica Pacifici, Simone Tiberini, Silvia M. Baio, Giovanni Broggi, Stefano Severi, Giovanni Paganelli. Eleven-Year Experience with the Avidin-Biotin Pretargeting System in Glioblastoma: Toxicity, Efficacy and Survival. *Open Journal of Nuclear Medicine. The Open Nuclear Medicine Journal*, 2012, 4, 14-20.
- A50** Vanazzi A, **Grana C**, Crosta C, Pruner G, Rizzo S, Radice D, Pinto A, Calabrese L, Paganelli G, Martinelli G. Efficacy of 90 Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma. *Hematol Oncol.* 2013 May 20.
- A51** Bertani, N Fazio, E Botteri, Chiappa A, M Falconi, **C M Grana**, L Bodei, D Papis, F Spada, B Bazzoli, B Andreoni. Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach. *Surgery.* 2014
- A52** E. Solfaroli Camillocci, G. Baroni, F. Bellini, V. Bocci, F. Collamati, M. Cremonesi, E. De Lucia, P. Ferroli, S. Fiore, **C.M. Grana**, M. Marafini, I. Mattei, S. Morganti, G. Paganelli, V. Patera, L. Piersanti, L. Recchia, A. Russomando, M. Schiariti, A. Sarti, A. Sciubba, C. Voena & R. Faccini. A novel radioguided surgery technique exploiting Beta- decays. *Sci Rep.* 2014 Mar 20;4:4401
- A53** Cremonesi M, Ferrari M, Botta F, Guerriero F, Garibaldi C, Bodei L, De Cicco C, **Grana CM**, Pedrol G, Orecchia R. Planning Combined Treatments of External Beam Radiation Therapy and Molecular Radiotherapy. *Cancer Biother Radiopharm.* 2014 Jul 9, Aug; 29(6):227-37
- A54** Gilardi L, **Grana CM**, Paganelli G. Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging. *Eur J Nucl Med Mol Imaging.* 2014 Nov;41(11):2090-2.
- A55** Marta Cremonesi, Carlo Chiesa, Lidia Strigari, Mahila Ferrari, Francesca Botta, Francesco Guerriero, Concetta De Cicco, Guido Bonomo, Franco Orsi, **Chiara Maria Grana**, Roberto Orecchia. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. *Front Oncol.* 2014 Aug 19;4:210. eCollection
- A56** Galimberti V, Manika A, Maisonneuve P, Corso G, Salazar Moltrasio L, Intra M, Gentilini O, Veronesi P, Pagani G, Rossi E, Bottiglieri L, Viale G, Rotmensch N, De Cicco C, **Grana CM**, Sangalli C, Luini A. Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease. *Eur J Surg Oncol.* 2014 Oct;40(10):1203-8.
- A57** Bodei L, Kidd M, Paganelli G, **Grana CM**, Drozdov I, Cremonesi M, Lepensky C, Kwekkeboom DJ, Baum RP, Krenning EP, Modlin IM. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. *Eur J Nucl Med Mol Imaging.* 2015 Jan;42(1):5-19. doi: 10.1007/s00259-014-2893-5.

A58 Bodei L, Cremonesi M, Kidd M, **Grana CM**, Severi S, Modlin IM, Paganelli G. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. *Thorac Surg Clin*. 2014 Aug;24(3):333-49. Review.

A59 Collamati F, Pepe A, Bellini F, Bocci V, Chiodi G, Cremonesi M, De Lucia E, Ferrari ME, Frallicciardi PM, **Grana CM**, Marafini M, Mattei I, Morganti S, Patera V, Piersanti L, Recchia L, Russomando A, Sarti A, Sciubba A, Senzacqua M, Solfaroli Camillocci E, Voena C, Pinci D, Faccini R. Toward radioguided surgery with β^- decays: uptake of a somatostatin analogue, DOTATOC, in meningioma and high-grade glioma. *J Nucl Med*. 2015 Jan;56(1):3-8.

A60 Intra M, Viale G, Vila J, **Grana CM**, Toesca A, Gentilini O, Galimberti V, Veronesi P, Luini A, Rotmensz N, Bagnardi V, Mattar D, Colleoni M. Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology. *Ann Surg Oncol*. 2015 Jul;22(7):2372-7

A61 Gilardi L, de Marinis F, **Grana CM**. PET/CT characterization of non-small-cell lung cancer heterogeneity. *Nucl Med Commun*. 2015 May;36(5):411-3.

A62 Bertani E, Falconi M, **Grana C**, Botteri E, Chiappa A, Misitano P, Spada F, Ravizza D, Bazolli B, Fazio N. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making. *Int J Surg*. 2015 Jun 11. S1743-9191(15)00286-1.

A63 Ianniello A, Sansovini M, Severi S, Nicolini S, **Grana CM**, Massri K, Bongiovanni A, Antonuzzo L, Di Iorio V, Sarnelli A, Caroli P, Monti M, Scarpi E, Paganelli G. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and ¹⁸F-FDG PET. *Eur J Nucl Med Mol Imaging*. 2015 Nov 27.

A64 Maffioli L, Florimonte L, Costa DC, Correia Castanheira J, **Grana C**, Luster M, Bodei L, Chinol M. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer. *Q J Nucl Med Mol Imaging*. 2015 Dec;59(4):420-38.

A65 Galetta D, Bellomi M, **Grana C**, Spaggiari L. Radio-Guided Localization and Resection of Small or Ill-Defined Pulmonary Lesions. *Ann Thorac Surg*. 2015 Oct;100(4):1175-80.

A66 Mariniello A, Bodei L, Tinelli C, Baio SM, Gilardi L, Colandrea M, Papi S, Valmadre G, Fazio N, Galetta D, Paganelli G, **Grana CM**. Long-term results of PRRT in advanced bronchopulmonary carcinoid. *Eur J Nucl Med Mol Imaging*. 2016 Mar;43(3):441-52.

A67 Galimberti V, Ribeiro Fontana SK, Maisonneuve P, Steccanella F, Vento AR, Intra M, Naninato P, Caldarella P, Iorfida M, Colleoni M, Viale G, **Grana CM**, Rotmensz N, Luini A.

Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. *Eur J Surg Oncol*. 2016 Mar;42(3):361-8.

A68 Preda L, Conte G, Bonello L, Giannitto C, Travaini LL, Raimondi S, Summers PE, Mohssen A, Alterio D, Cossu Rocca M, **Grana C**, Ruju F, Bellomi M. Combining standardized uptake value of FDG-PET and apparent diffusion coefficient of DW-MRI improves risk stratification in head and neck squamous cell carcinoma. *Eur Radiol*. 2016 Mar 10

A69 Travaini LL, Zampino MG, Colandrea M, Ferrari ME, Gilardi L, Leonardi MC, Santoro L, Orecchia R, **Grana CM**. PET/CT with Fluorodeoxyglucose During Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. *Ecancermedicalscience*. 2016 Mar 29;10:629.

A70 Antonello Enrico Spinelli, Marco P. Schiariti, **Chiara M. Grana**, Mahila Ferrari, Marta Cremonesi, Federico Boschi. Cerenkov and radioluminescence imaging of brain tumor specimens during neurosurgery. *J. Biomed. Opt.* 21(5), 050502 (2016)

A71 Gilardi L, Vadrucchi M, **Grana CM**. Multiple vertebral hemangiomas: a potential pitfall in ⁶⁸Ga-DOTATOC PET/CT interpretation. *Endocrine*. 2016 Aug 12.

A72 E. Solfaroli Camillocci, M. Schiariti, V. Bocci, A. Carollo, G. Chiodi, M. Colandrea, F. Collamati, M. Cremonesi, R. Donnarumma, M. E. Ferrari, P. Feroli, F. Ghielmetti, **C. M. Grana**, M. Marani, S. Morganti, C. Mancini Terracciano, M. Patan, G. Pedrolì, B. Pollo, L. Recchia, A. Russomando, M. Toppi, G. Traini, R. Faccini. First Ex-Vivo Validation of a Radioguided Surgery Technique with beta- Radiation. *Phys Med*. 2016 Sep 2. pii: S1120-1797(16)30916-4. doi: 10.1016/j.ejmp.2016.08.018.

A73 LL Travaini, Chiappa A, Monteleone M, Orecchia R, **CM Grana**. A decisive role of ¹⁸F]FDG PET/CT for diagnosis of neoplastic vascular thrombosis: report of a case. *International Journal of Surgery and Research - 2016 August Int J Surg Res*. 3(4), 52-54

A74 Emilio Bertani, Nicola Fazio, Davide Radice, Claudio Zardini, **Chiara M Grana**, Lisa Bodei, Luigi Funicelli, Carlo Ferrari, Francesca Spada, Stefano Partelli, Massimo Falconi.

Resection of the primary tumor followed by peptide receptor radionuclide therapy as upfront strategy for the treatment of G1-G2 pancreatic neuroendocrine tumors with unresectable liver metastases. *Ann Surg Oncol*. 2016 Sep 9.

A75 Manuela Vadrucchi, Laura Gilardi, **Chiara Maria Grana**. Breast Cancer Incidentally Detected by ¹⁸F-Choline PET/CT in a Patient With Recurrent Prostate Carcinoma. *Clin Nucl Med*. 2016 Sep 7.

A76 Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, **Grana CM**, Bodei L, Paganelli G. Long-Term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE. *Eur J Nucl Med Mol Imaging*. 2017 Feb;44(2):352.

A77 Lambrescu I, Fica S, Martins D, Spada F, Cella C, Bertani E, Rubino M, Gibelli B, **Grana C**, Bonomo G, Funicelli L, Ravizza D, Pisa E, Zerini D, Ungaro A, Fazio N. Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives. 2017 Apr;55:46-56

A78 Gilardi L, Vadrucchi M, Pirola S, **Grana CM**. Oncocytoma as a growing FDG-avid adrenal mass on serial 18F-FDG PET/CT imaging: A potential pitfall in oncological evaluation. *Rev Esp Med Nucl Imagen Mol*. 2017 May - Jun;36(3):201-203.

A79 Ferrari M, Travaini LL, Ciardo D, Garibaldi C, Gilardi L, Glynn-Jones R, **Grana CM**, Jereczek-Fossa BA, Marvaso G, Ronchi S, Leonardi MC, Orecchia R, Cremonesi M. Interim 18FDG PET/CT during radiochemotherapy in the management of pelvic malignancies: A systematic review. *Crit Rev Oncol Hematol*. 2017 May;113:28-42.

A80 Martins D, Spada F, Lambrescu I, Rubino M, Cella C, Gibelli B, **Grana C**, Ribero D, Bertani E, Ravizza D, Bonomo G, Funicelli L, Pisa E, Zerini D, Fazio N; IEO ENETS Center of Excellence for GEP NETs Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors. *Target Oncol*. 2017 Jun 21. doi: 10.1007/s11523-017-0506-5.

A81 Garibaldi C, Ronchi S, Cremonesi M, Gilardi L, Travaini L, Ferrari M, Alterio D, Kaanders JHAM, Ciardo D, Orecchia R, Jereczek-Fossa BA, **Grana CM**. Interim 18F-FDG PET/CT During Chemoradiation Therapy in the Management of Head and Neck Cancer Patients: A Systematic Review. *Int J Radiat Oncol Biol Phys*. 2017 Jul 1;98(3):555-573.

A82 Cremonesi M, Gilardi L, Ferrari ME, Piperno G, Travaini LL, Timmerman R, Botta F, Baroni G, **Grana CM**, Ronchi S, Ciardo D, Jereczek-Fossa BA, Garibaldi C, Orecchia R. Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review. *Eur J Nucl Med Mol Imaging*. 2017 Jul doi: 10.1007/s00259-017-3762-9.

A83 Corso G, **Grana CM**, Gilardi L, Baio SM, De Lorenzo D, Maisonneuve P, Rotmensz N, Ballardini B, Lissidini G, Ratini S, Bassi FD, Veronesi P, Galimberti V. Feasibility of lymphoscintigraphy for sentinel node identification after neo-adjuvant therapy. *Ann Ital Chir*. 2017;88:201-205.

A84 Russomando A.; Schiariti M.; Bocci V.; Colandrea M.; Collamati F.; Cremonesi M.; Ferrari M.E.; Ferrolì P.; Ghielmetti F.; Ghisini R., **Grana CM**.; Mancini Terracciano C.; Marafini M.; Mirabelli R.; Morganti S.; Papi S.; Patane' M.; Pedrolì G.; Pollo B.; Solfaroli Camillocci E.; Traini G.; Faccini R. The β^- radio-guided surgery: method to estimate the minimum injectable activity from ex-vivo test. *EJNMMI Physics* 2017 (submitted).

A85 Peri M, Botteri E, Ungaro A, Spada F, **Grana CM**, Gasparri R, Spaggiari L, Romentz N, Badalamenti G, Russo A, Fazio N A single-Institution retrospective analysis of metastatic bronchial neuroendocrine tumors with a focus on the recurrence pattern. *J Clin Oncol*. 2017(submitted)

A86 Guarize J; Casiraghi M; Donghi S; Casadio C; Diotti C; Filippi N; Di Tonno C; Midolo V; Maisonneuve P; Brambilla D; **Grana C**; Petrella F; Spaggiari L Endobronchial ultrasound transbronchial needle aspiration in positron emission tomography (PET) positive lymphadenopathies in treated cancer patients. *ERJOR* 2017 (submitted)

A87 Partelli S, Bertani E, Bartolomei M, Perali C, Muffatti F, **Grana CM**, Schiavo Lena M, Doglioni C, Fazio N, Zamboni G, Falconi M. Surgical and Oncological Outcomes of Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Resectable or Potentially Resectable Pancreatic Neuroendocrine Neoplasms. *Ann Surg* 2017 (submitted).

A88 Cremonesi M, Garibaldi C, Timmerman R, Ferrari M, Ronchi S, **Grana MC**, Travaini L, Gilardi L, Starzynska A, Ciardo D, Orecchia R, Jereczek BA, Leonardi Cm. Interim 18F-FDG-PET/CT during chemo-radiotherapy in the management of oesophageal cancer patients. A systematic review. *Radiother. Oncol*. 2017 (submitted revision).

BOOKS CHAPTERS

C1 - Paganelli G, Chinol M, **Grana C**, Fiorenza M, Cremonesi M, Franceschini R, Tarditi L, Pecorale A, Meares C, Corti A, Siccardi AG. Therapy trials in cancer patients using an improved 3-step pretargeting approach. In "Radioactive isotopes in Clinical Medicine and Research XXII" Ed. H. Bergmann, A. Kroiss and H. Sinzinger Birkhauser Verlag Basel/Switzerland, 513-517, 1996.

C2 - M. Chinol, **C. Grana**, R. Gennari, M. Cremonesi, J. G. Geraghty and G. Paganelli. Pretargeted Radioimmunotherapy of Cancer. In "Radioimmunotherapy of Cancer". Ed P. G. Abrams and A. R. Fritzberg. 169-193, 2000.

C3 - Stefano Papi, **Chiara Maria Grana**, Mirco Bartolomei, Laura Ravasi, Marta Cremonesi, Mahila Ferrari, Luigi Martano, Lucia Garaboldi, Marco Chinol, and Giovanni Paganelli PRETARGETED RADIOIMMUNOTHERAPY IN CANCER: AN OVERVIEW;, "Method of Cancer Diagnosis, Therapy and Prognosis", edit. M.A. Hayat; 1st Edition., 2010, L, 478 p. 44 illus., 22 in color., Hardcover ISBN: 978-90-481-3185-3

C4 – **Chiara M Grana**, Marta Cremonesi, M Lopera Sierra, Giovanni Paganelli. Tratamiento del linfoma non-Hodgkin en medicina nuclear; Cap 34. Medicina Nuclear en la práctica clínica, Segunda edición; Editores: Ángel Soriano Castrejón, Pep Martín-Comín, Ana García Vicente, 2012

C5 – **Chiara Maria Grana** and Giovanni Paganelli. Radioimmunotherapy in Brain Tumors in "Nuclear Medicine Therapy. Principles and Clinical Applications". Ed Springer 2013, pp 113-131

C6 –**Chiara Maria Grana** and Giovanni Paganelli. "Yttrium-90 Labelled Anti-CD20 Radioimmunotherapy with Stem Cells Support.". Springer: Nuclear Medicine Therapy (Medical Radiology/Radiation Oncology Section) Ed. R.P. Baum, Springer, 2014

C7 L Bodei, M. Kidd, L. Gilardi, D. Volterrani, G. Paganelli, **C.M. Grana**, I. Modlin, Nuclear Oncology: From Phatophysiology to clinical applications – Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors. Ed Springer 2017 – in press

C8 L Bodei, L. Gilardi, D. Volterrani, G. Paganelli, **C.M. Grana**, M. Kidd I. Modlin, Nuclear Oncology: From Phatophysiology to clinical applications – Radionuclide Therapy - Ed Springer 2017